Table 3

OR and 95% CIs for urinary phytoestrogen excretion rates in relation to breast cancer risk, stratified by levels of BMI and WHR, the Shanghai Breast Cancer Study, 1996–1998

BMI or WHR (by median)Urinary excretion rate of isoflavonoids by tertilea
T1 (low)T2T3P for trend
Total isoflavonoids
 Cases/controls53/3837/3927/40
 All subjects combined1.000.79 (0.42–1.49)0.46 (0.22–0.95)0.04
 BMIb<251.001.68 (0.70–4.06)0.54 (0.21–1.41)0.34
≥251.000.30 (0.10–0.87)0.38 (0.13–1.17)0.06
P for interaction, 0.23
 WHRc<0.841.000.80 (0.35–1.84)0.66 (0.28–1.54)0.33
≥0.841.000.80 (0.27–2.33)0.18 (0.05–0.68)0.02
P for interaction, 0.36
Total lignans
 Cases/controls43/3951/3823/40
 All subjects combined1.001.06 (0.54–2.08)0.50 (0.23–1.10)0.09
 BMIb<251.001.53 (0.61–3.86)0.70 (0.26–1.88)0.37
≥251.000.72 (0.27–1.87)0.27 (0.07–1.10)0.08
P for interaction, 0.71
 WHRc<0.841.001.04 (0.45–2.41)0.86 (0.32–2.29)0.67
≥0.841.001.33 (0.42–4.22)0.17 (0.04–0.71)0.02
P for interaction, 0.38
  • a Cases and controls were categorized according to the tertile level of controls.

  • b Adjusted for age at first live birth, ever diagnosed with fibroadenoma, total meat intake, and ever physically active.

  • c Additionally adjusted for BMI.